Because of its effects on proteasome, bortezomib has been extensively studied in clinical trials for the treatment of different types of cancer and is nowadays used in the treatment of multiple myeloma and mantle cell lymphoma; whether LONP1 inhibition contributes to the therapeutic benefit of bortezomib or is an off-target effect is still a matter of debate. This evidence concerns the gene LONP1 and cancer.